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Abstract Purpose: Pentraxin 3 (PTX3) is an inflammatory mediator produced by neutrophils, macrophages, myeloid dendritic and endothelial cells. During sepsis a massive inflammatory activation and coagulation/fibrinolysis dysfunction occur. PTX3, as a mediator of inflammation, may represent an early marker of severity and outcome in sepsis. Methods: This study is based on a prospective trial regarding the impact of glycemic control on coagulation in sepsis. Ninety patients admitted to three general intensive care units were enrolled when severe sepsis or septic shock was diagnosed. At enrollment, we recorded sepsis signs, disease severity, coagulation activation [prothrombin fragments 1 ? 2 (F 1?2 )] and fibrinolysis inhibition [plasminogen activator inhibitor-1 (PAI-1)]. We measured plasma PTX3 levels at enrollment, everyday until day 7, then at days 9, 11, 13, 18, 23 and 28. Mortality was recorded at day 90. Results: Although not different on day 1, PTX3 remained significantly higher in non-survivors than in survivors over the first 5 days (p = 0.002 by general linear model). On day 1, PTX3 levels were higher in septic shock than in severely septic patients (p = 0.029). Day 1 PTX3 was significantly correlated with platelet count (p \ 0.001), SAPS II score (p = 0.006) and SOFA score (p \ 0.001). Day 1 PTX3 was correlated with F 1?2 concentration and with PAI-1 activity and concentration (p \ 0.05 for all). Conclusions: Persisting high levels of circulating PTX3 over the first days from sepsis onset may be associated with mortality. PTX3 correlates with severity of sepsis and with sepsisassociated coagulation/fibrinolysis dysfunction.
Introduction
Pentraxins are a superfamily of evolutionarily conserved proteins involved in the acute phase of inflammation [1] . The classic short pentraxin C-reactive protein (CRP) is produced in the liver in response to inflammatory signals, prominently interleukin 6 (IL-6). CRP is involved in the innate resistance to microbes and the scavenging of cellular debris and extra-cellular matrix components [2] . The prototypic long pentraxin 3 (PTX3), like the classical short pentraxins, acts as a receptor for innate immunity activation. However, it differs from CRP in molecular structure, gene organization, cellular source, inducing stimuli and ligands recognition. PTX3 values in healthy subjects are low (i.e., \2 ng/ml). PTX3 can be rapidly produced and released by mononuclear phagocytes, neutrophils, fibroblasts and epithelial and endothelial cells in response to primary inflammatory signals [e.g., IL-1 and tumor necrosis factor-a (TNFa)] [3, 4] . PTX3 plays a central role in the early phases of inflammation: it recognizes microbial moieties, activates the classical pathway of complement and facilitates recognition by macrophages and dendritic cells [5] . Moreover, evidence is growing regarding an interaction between PTX3 and tissue factor (TF) expression, which promotes coagulation activation during sepsis [6] [7] [8] .
Sepsis is characterized by an inflammatory activation, originating at the primary infection site. As infection persists, many different molecular mediators are poured into the systemic circulation, causing the typical sepsis-associated signs and symptoms and secondary organ failures (severe sepsis or septic shock). These deleterious effects happen also by means of coagulation dysfunction (e.g., an imbalance between coagulation activation and fibrinolysis) [9, 10] . TNFa, IL-6 and CRP are among the most important molecules involved in the systemic consequences of severe sepsis and septic shock [11] .
PTX3 is elevated and correlates with severity and outcome in several infectious and inflammatory human diseases and conditions [12] [13] [14] [15] [16] . Moreover, in post hoc subgroup analyses of two published articles [12, 17] , plasma PTX3 levels were higher in severely septic and septic shock patients in comparison to healthy controls and septic subjects.
Investigation of PTX3 during sepsis may lead us to a deeper understanding of the pathophysiology of this syndrome and possibly to the development of more effective therapies against it.
Specifically, in this study we tested the hypothesis that persisting high levels of plasma PTX3 in the first days after sepsis onset may represent an early marker of severity and mortality in septic patients.
Materials and methods

Study design
This article reports results obtained from measures and analyses performed on samples and data collected during a randomized controlled clinical trial [18] . The main purpose of the trial was to study the effects of glycemic control on the fibrinolytic pathway and the role of different inflammatory mediators in severe sepsis and septic shock patients. Data were collected between December 2004 and March 2007 at three large university hospital intensive care units (ICU). Written informed consent was obtained from each subject before enrollment. In case of temporary inability due to the patient's clinical conditions, consent was delayed until the patient was able to express it. Data and samples already collected were destroyed whenever the patient refused to give consent. The study was approved by the Institutional Review Board of each hospital.
Study population
Patients were enrolled as soon as they met previously defined criteria for severe sepsis or septic shock [19] . Exclusion criteria were: age below 16 years, type I diabetes mellitus, hematologic malignancies or bone marrow transplant, and likelihood of early death because of the underlying disease.
Interventions
At enrollment, each patient was allocated by block randomization to have blood glucose levels managed for the entire study period either by a tight glycemic control strategy (TGC group, 45 patients) or by a conventional glycemic control strategy (CGC group, 45 patients). Glucose control and insulin treatment in the two groups were performed as described by Van den Berghe et al. [20] . The study period lasted 28 days.
Data collection
Sex, age, body mass index (BMI), ICU admission type, co-morbidities, presence of severe sepsis or septic shock, primary infection site (i.e., pulmonary, abdominal, urinary tract or other), Simplified Acute Physiology Score II (SAPS II) values [21] , arterial blood gas values, heart rate, serum creatinine and the presence of artificial renal support, serum bilirubin, blood platelets and white cells count, number of organ failures and Sepsis-related Organ Failure Assessment (SOFA) score [22] were recorded at enrollment (day 1). Plasma CRP, IL-6, TNFa, prothrombin fragments 1 ? 2 (F 1?2 ), plasminogen activator inhibitor-1 (PAI-1) concentration and activity, and PTX3 levels were measured on day 1. CRP, IL-6, TNFa and PTX3 were assayed also every day for the first week, then every other day until day 13 and then every 5th day until the end of the study or until ICU discharge or death. Mortality was assessed 90 days after enrollment in order to detect all possible sepsis-related deaths, which can occur also after the acute phase by means of residual organ dysfunctions [23] .
Laboratory measurements
Plasma samples were stored at -80°C until mediator levels were measured. IL-6, CRP and TNFa were assayed by standard commercial kits. F 1?2 , reflecting the amount of generated thrombin, were measured as biochemical markers of coagulation activation. Concentration and activity of PAI-1 were determined as markers of fibrinolysis inhibition (the higher levels corresponding to greater inhibition) [18] . PTX3 was assayed by sandwich ELISA (detection limit 0.1 ng/ml) as previously described [14] . ELISA for PTX3 does not cross-react with the short pentraxins CRP and serum amyloid P.
Statistical analysis
Statistical analysis was performed using SPSS 14.0 (SPSS Inc. Chicago, IL). Variables not normally distributed (Kolmogorov-Smirnov test: IL-6, TNFa and PTX3) were log-transformed for analyses. P values of less than 0.05 were considered as statistically significant. Variables are reported as mean ± standard deviation, unless otherwise indicated. Comparisons between treatment groups, survivors and non-survivors, or between different clinical classes (e.g., severe sepsis vs. septic shock patients) were carried out using Student's t test or ANOVA models (Bonferroni post hoc test was used to analyze differences in PTX3 levels between patients with different primary infection sites), and chi-square test or Fisher's exact test for quantitative and qualitative variables, respectively. Regressions were computed and tested according to a simple linear model. We analyzed differences in plasma PTX3 between TGC and CGC groups and between survivors and non-survivors from day 1 to day 5 by a general linear mixed model (GLM) for repeated measures (for the reasons why this analysis was performed only over the first 5 days, see 'limitations' in ''Discussion''). The model took into account treatment group and outcome as a between-subject factor, and the effect of time as a withinsubject factor. We constructed receiver-operator characteristic (ROC) curves with the values of day 5:day 1 level ratios of PTX3, IL-6, TNFa and CRP (i.e., the relative variation of each mediator level from day 1 to day 5) to assess if persisting high mediator levels are able to predict mortality. We also calculated the positive likelihood ratios and the increase in death probability per 0.01 increase of day 5:day 1 level ratios. Day 5:day 1 level ratios were chosen to further investigate the relationship between persisting high PTX3 levels and outcome (see 'limitations' in ''Discussion''). Table 1 offers a description of the 90 subjects enrolled in the study. Four patients (5%) died within 5 days from enrollment, 17 (19%) died in the ICU and 27 (30%) died by day 90.
Results
Study population characteristics
Day 1 PTX3 values and correlations with other inflammatory mediators
On day 1, PTX3 levels were higher than normal in all patients (i.e., C2 ng/ml) (ONLINE RESOURCE Figure 1A) and were loosely but significantly correlated with IL-6 (R 2 = 0.046, p = 0.045) and TNFa (R 2 = 0.126, p = 0.001), but not with CRP (Table 2 ).
PTX3 prognostic significance
Although not different at day 1 (Table 1) , circulating PTX3 levels remained significantly higher in non-survivors than in survivors over the first 5 days from the onset of sepsis (GLM p = 0.002) (Fig. 1a) , whereas CRP, IL-6 and TNFa (Fig. 1b-d ) time courses were not associated with patients' outcome.
The ROC curves analysis showed that, among the four mediators tested, only PTX3 day 5:day 1 level ratios were able to discriminate between survivors and non-survivors (area under the curve 0.73, p \ 0.01) (Fig. 2) . A value of day 5:day 1 PTX3 of 0.76 predicted death with 64% specificity and 72% sensitivity (positive likelihood ratio 1.98). Every 0.01 increase in day 5:day 1 PTX3 levels increased the probability of death by 3.7% (95% confidence interval 1.2-6.3%).
Day 1 patients' characteristics associated with outcome
On day 1, survivors had significantly higher arterial pH values than non-survivors (7.39 ± 0.08 vs. 7.35 ± 0.1, p = 0.05), whereas SOFA score values were lower (8 ± 3 vs. 10 ± 3, p = 0.03) ( Table 1) . Survivors required less artificial renal support therapy at enrollment (5 vs. 9%, p = 0.01) ( Table 1) .
Day 1 mediator levels and disease severity Circulating PTX3, IL-6 and TNFa levels were loosely but significantly correlated with heart rate, whereas CRP levels were not (Table 2 ). PTX3 was higher in patients with septic shock in comparison to patients with severe sepsis (274.41 ± 321.92 vs. 114.95 ± 129.93 ng/ml, p = 0.029) (ONLINE RESOURCE Figure 2A ), whereas CRP, IL-6 and TNFa were not (ONLINE RESOURCE Figure 2B-D) .
PTX3, but not IL-6, CRP or TNFa, was significantly correlated with serum creatinine levels ( Table 2 ). PTX3 and TNFa were significantly related to blood platelets (Table 2) . PTX3 ( Fig. 3a) and TNFa (Fig. 3d) increased with the number of organ failures; again, CRP and IL-6 did not (Fig. 3b,  c) . PTX3, IL-6 and TNFa levels ( Table 2 ), but not those of CRP (Table 2) , were significantly correlated with SOFA scores. PTX3 was related to SAPS II scores, but not IL-6, CRP or TNFa (Table 2 ). PTX3 and, more loosely, IL-6 and TNFa were significantly correlated with PAI-1 activity and concentration, but CRP was not (Table 2 ). PTX3 was loosely but significantly related to F 1?2 concentration (Table 2) , whereas the other three mediators were not. Among the four mediators we measured, only PTX3 levels differed significantly among patients with different primary infection sites (p = 0.021): patients with urinary tract infections (UTI) had the highest values (p = 0.01 vs. pulmonary and p = 0.05 vs. abdominal). Patients with UTIs (n = 7) also had significantly higher SOFA (11 ± 3 vs. 9 ± 3, p = 0.03) and SAPS II (53 ± 17 vs. 42 ± 14, p = 0.04) scores than the rest of the population, even though mortality among UTI patients was 0%.
Effects of glycemic control CRP, IL-6, TNFa and PTX3 levels did not differ between the TGC and CGC group for the first 5 days from enrollment (p = 0.221).
Discussion
The main findings of this study can be summarized as follows: (1) persistently high plasma levels of circulating PTX3 for the first days after diagnosis of severe sepsis and septic shock are associated with poorer outcome; (2) plasma PTX3 is elevated and correlates with disease severity, organ dysfunction and coagulation activation markers in severe sepsis and septic shock; (3) PTX3 showed a stronger correlation with clinical parameters and outcome than any of the other biomarkers analyzed (IL-6, TNFa and CRP).
We found that at enrollment non-survivors had lower pH values, higher SOFA scores and a higher need for renal replacement therapy, three established markers of sepsis severity [21, 22] . However, neither PTX3 nor any other of the three measured inflammatory mediators differed between survivors and non-survivors on day 1. These data appear in contrast with our previous findings on PTX3 in ARDS [12] . However, ARDS may have etiologies other than sepsis and consequently different inflammatory pathways [24, 25] . We hypothesized that, if not day 1 PTX3 levels, then the time course of PTX3 over the first days from diagnosis may predict mortality in sepsis. In fact, circulating PTX3 over the first 5 days from Table 2 Correlation among day 1 pentraxin 3, interleukin-6, tumor necrosis factor a TNFa, IL-6 and CRP, at variance, remained similar. Moreover, a decrease of plasma PTX3 levels from day 1 to day 5 of less than 24% predicted death with good specificity and sensitivity (Fig. 2) . The persistence of high levels of PTX3 during the first days from diagnosis may be related to an unresolving infection that may still be triggering and maintaining the inflammatory response mediated by PTX3 (i.e., neutrophils and complement activation, etc.) [4, 5] , and therefore may lead to higher morbidity and mortality [26] . Further studies to investigate the role of PTX3 in the outcomes of septic patients are needed, particularly to disclose whether PTX3 is of any use in guiding clinical decisions. On day 1, PTX3 was significantly associated with signs of sepsis, with markers of the systemic severity of sepsis, with number of organ failures and with blood platelet count, F 1?2 and PAI-1 (coagulation/fibrinolysis dysfunction markers). These results are consistent with previous studies [6, 12, 13, 16] and add consistency to the theory of the importance of PTX3 in sepsis. However, whether PTX3 plays a direct role or is just a marker of an established injury remains to be elucidated. Data from the literature are somewhat conflicting: (1) on one hand, recent studies have shown that PTX3 may play an early central role in infections [27] [28] [29] [30] [31] . Moreover, in the present study, PTX3 levels were directly correlated with sepsis-associated coagulation/fibrinolysis dysfunction, a key factor for sepsis severity and most likely mortality [18] . Recently, He and coworkers showed that PTX3 production is associated with TF expression and activation during lung inflammation [8] . In keeping with this and previous findings [6, 7] , our results strengthen the hypothesis of a link between PTX3 and sepsis-related dysregulation of the coagulation/fibrinolysis system. (2) On the other hand, recent data suggest that PTX3 is protective in an experimental mouse model of AMI [32] . The role of PTX3 in infectious human disease (i.e., marker vs. cause) and in coagulation dysfunction deserves further investigation (e.g., through animal models).
Glucose has been shown to be a powerful proinflammatory mediator and tight glycemic control to exert anti-inflammatory effects in critically ill patients [33] . However, in the present study, PTX3 levels were not affected by tight glycemic control. Up to now, it has been difficult to find a clinical therapeutic approach that can mitigate sepsis or lung injury through inhibition of PTX3 production [4] . Therefore, the role of PTX3 in the pathogenesis of severe inflammatory/infectious diseases remains unclear [1] . Even though a growing set of clinical data suggests that PTX3 might be a key pathogenetic factor [12] [13] [14] [15] [16] [17] , more pre-clinical studies are required to support this hypothesis [8, [34] [35] [36] [37] .
In the present study, day 1 TNFa, IL-6 and CRP seem to correlate poorly with markers of sepsis severity and organ dysfunctions. Day 1 PTX3 correlates with a broader number of severity parameters, but the regression coefficients are again very low. One reason for these findings could be that we drew the first blood sample as soon as we diagnosed severe sepsis or septic shock, but this may have meant hours from the real beginning of the activation of inflammation. Therefore, the chosen timing may have Although not different at day 1 (see Table 1 ), circulating PTX3 levels (a) remained significantly higher in non-survivors than in survivors over the first 5 days [p = 0.002 by general linear model (GLM)], while CRP (b), IL-6 (c) and TNFa (d) time courses were not associated with patients' outcome (n = 86, 95% of the study population). Values are shown as mean ± standard deviation; dashed lines represent normal values been too late for primary inflammatory signals like PTX3, TNFa and IL-6, and too early for CRP to be adequately produced by the liver [2, 11] . More studies with a higher number of subjects enrolled are warranted to verify if PTX3 can be a solid marker for stratifying sepsis severity and guiding aggressive and costly therapies [38, 39] .
This study has a number of limitations. First, plasma samples were assayed only after study enrollment was completed; however, this is a method widely accepted and used [14] . Second, we analyzed differences in plasma PTX3 between survivors and non-survivors only over the first 5 days from diagnosis of severe sepsis/septic shock. Although this may seem an arbitrary choice, it is justified for two reasons: (1) we sought a satisfactory compromise between sample size and statistical power: at 5 days we could still analyze data from nearly all the patients (95%) without introducing assumptions in the statistical model (i.e., missing at random); (2) in our previous study on PTX3 levels in ARDS patients, PTX3 levels differed between survivors and non-survivors on days 1, 2, 3 and 5 from enrollment, becoming similar thereafter. Third, we did not look for any correlation between mediators' levels after day 5 and sepsis severity and outcome. The aim of our study was to verify if early high plasma levels of these mediators can be valuable markers of severity and outcome in sepsis. Therefore, we focused on the acute initial rather than on the later phase of sepsis. Mediator levels in the established phase of sepsis could be the object of future analyses. 
Conclusions
In this study, we describe that persisting high levels of plasma PTX3 over the first 5 days from diagnosis are correlated with poorer outcome in a relatively large population of severely septic and septic shock patients. PTX3 levels are also associated with disease severity, secondary organ failure and coagulation/fibrinolysis dysfunction in these patients. The relationship between PTX3 and the pathophysiology, severity and outcome of sepsis deserves further investigation.
